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Abstract
Objective To investigate whether discrepancies in trials of use of bone
marrow stem cells in patients with heart disease account for the variation
in reported effect size in improvement of left ventricular function.
Design Identification and counting of factual discrepancies in trial reports,
and sample size weighted regression against therapeutic effect size.
Meta-analysis of trials that provided sufficient information.
Data sources PubMed and Embase from inception to April 2013.
Eligibility for selecting studiesRandomised controlled trials evaluating
the effect of autologous bone marrow stem cells for heart disease on
mean left ventricular ejection fraction.
Results There were over 600 discrepancies in 133 reports from 49 trials.
There was a significant association between the number of discrepancies
and the reported increment in EF with bone marrow stem cell therapy
(Spearman’s r=0.4, P=0.005). Trials with no discrepancies were a small
minority (five trials) and showed a mean EF effect size of −0.4%. The
24 trials with 1-10 discrepancies showed a mean effect size of 2.1%.
The 12 with 11-20 discrepancies showed a mean effect of size 3.0%.
The three with 21-30 discrepancies showed a mean effect size of 5.7%.
The high discrepancy group, comprising five trials with over 30
discrepancies each, showed a mean effect size of 7.7%.
Conclusions Avoiding discrepancies is difficult but is important because
discrepancy count is related to effect size. The mechanism is unknown
but should be explored in the design of future trials because in the five
trials without discrepancies the effect of bone marrow stem cell therapy
on ejection fraction is zero.
Introduction
Autologous bone marrow stem cells offer an exciting
opportunity for improvement of left ventricular function, reverse
remodelling, and scar size reduction1 in patients with ischaemic
heart disease.2 Results, however, have been conflicting. The
reason for the differences between the various trials of effect
on left ventricular function has so far not been identified.
Meta-analyses have confirmed a significant positive effect on
average but have found no clear explanation for the conflicts
between individual trials.1 3 4
It has recently been discovered that some pioneering trials of
autologous bone marrow stem cells have unexplained
discrepancies that cast doubt on their validity.5 It was not
possible to report this directly in the journals that published the
trials.5 Discrepancies in reports have never been systematically
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explored as a possible explanatory variable for the effect size
of autologous bone marrow stem cells on ejection fraction.
We examined reports of the randomised controlled trials of bone
marrow stem cell therapy for discrepancies of design, methods,
or results and examine the relation between number of
discrepancies and effect sizes reported. We defined a
discrepancy as two (or more) reported facts that cannot both be
true because they are logically or mathematically incompatible.
Methods
Search strategy and eligibility criteria
We searched Embase and PubMed (1966 to April 2013), using
the following search strategy: (“bone marrow cell” OR “bone
marrow cells” OR “stem cells” OR “stem cell” OR “progenitor
cell” OR “progenitor cells”) AND (“myocardial infarction” OR
“coronary artery disease” OR cardiomyopathy OR “heart
failure”) AND random*.
We also manually searched citation lists1 5 and PubMed links
to related citations. We included trials that met the following
criteria:
• Trial reporting the effect on mean ejection fraction of
infusion of autologous stem cells derived from bone
marrow in patients with acute or established cardiac disease
• At least one publication by the authors described it as
randomised
• Available through our institution and in a language
understood well by at least one investigator.
For each trial identified by this method, we used the international
standard randomised controlled trial number registry (isrctn.org),
ClinicalTrials.gov registry, PubMed, Google, and manual
evaluation of references to search for other reports from that
trial published until end of April 2013.
Data extraction
Two authors (ANN and SJ) extracted data from each trial, with
disputes resolved by a third author (MJS). When the ejection
fraction was measured by more than one imaging technique
(magnetic resonance imaging (MRI), echocardiography,
radionuclide imaging, left ventriculography), we used the data
from the technique specified as the primary endpoint. If this
was not defined, we used the technique that was highlighted in
the abstract or (if the abstract was not specific) given priority
in the conclusion or (if not mentioned in either) given priority
in the results.When the ejection fraction effect size was reported
at multiple time points, we used that of the longest follow-up.
We defined the ejection fraction effect size6 as the change in
ejection fraction in the active arm minus the change in ejection
fraction in control arm. We used this if it was stated directly in
the trial. If it was not directly stated, we calculated it from the
changes provided in each arm or, when these were not provided,
from the baseline and follow-up values in each arm.
We used the standard error of the effect size if it was stated
explicitly in the trial. If the confidence interval of the effect size
was given instead, we extracted the standard error. If only the
standard errors or standard deviations or confidence intervals
of the changes in each arm were provided, we then extracted
the two standard deviations and sample sizes and used them to
calculate the standard error of the estimate.
Detection of discrepancies
The trials were then examined for discrepancies, which were
categorised into the following three types5:
1. Discrepancies in the design—for example, conflicting
statements as to whether the studywas randomised (tabulated
in appendix 1)
2. Discrepancies inmethods and baseline characteristics—for
example, sample or subgroup sizes that could not be an
integer number of patients (listed in appendix 2)
3. Discrepancies in results—for example, conflicts between
tables and figures or impossible values (listed in appendix
3).
Eight authors (ANN, DPF, GDC, HD, JPH,MM,MJS, SJ) read
all the reports, except those of the four trials for which the
discrepancies had already been found and published.5 Proposed
discrepancies were discussed. A discrepancy was declared valid
for inclusion in the study only if no member of the group could
find a valid explanation.
Contradictions in numerical values were considered as
discrepancies but errors in spelling or grammar were not. If the
same conflicting statements appeared more than once (for
example, a trial repeatedly described as randomised in one
publication, and repeatedly described as accepter-rejecter in
another), this was considered a single discrepancy.
Trials, and their reports, were coded with a “t” number or “r”
number, respectively. Appendix 4 provides a decoded list of
trials and reports with web links to the sources. Each discrepancy
was numbered with a three digit code after the two digit “t”
number. The first digit of the discrepancy code was allocated
according to the type of discrepancy—that is, 1, 2, or 3, as listed
above.
Of the trials, four had already undergone this process of
identification and checking of discrepancies therefore for these
we used the discrepancies as previously published by our group5
(t07, t08, t21, and t49). Because the present publication focuses
on counting discrepancies, where our previous report5 listed
more than one discrepancy on a single row, we now separated
these on to individual rows.
Assessing risk of bias
Risk of bias in the included trials was assessed with the
Cochrane Collaboration’s risk of bias assessment tool (see
appendix 5). Each trial was assessed by two independent
observers and any differences resolved by a third observer.
Data analysis
We visualised the relation between the ejection fraction effect
size and the discrepancy count with a scatter plot and quantified
it with Spearman’s rank correlation coefficient. It was further
visualised with a histogram with trials grouped by the number
of discrepancies in intervals of 10. Means were weighted by
sample size. We constructed a funnel plot of the data and used
Egger’s test to assess asymmetry.7
Ameta-analysis was conducted for trials that provided sufficient
data to weight the effect size estimates by a function of the
reciprocal of the square of the standard error of the effect size
estimate. We pooled the data on ejection fraction effect size for
this subset of trials using a random effects model and present
them as weighted mean differences with 95% confidence
intervals.
As part of an exploratory analysis we performed univariate and
multivariate linear regression analyses including the discrepancy
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count, sample size, and the five specific domains of the
Cochrane risk of bias tool as predictor variables for the effect
size. Any aspect of bias that was agreed to be “unclear” was
treated as a “no.” The multivariate model was built by stepwise
backwards selection based on the Akaike information criterion.8
Data analysis was carried out with R (version 3.0.2, R
Foundation),9 the graphics package ggplot2 (version 0.9.0),10
and the meta-analysis package metafor (version 1.9).
Results
Figure 1 shows how we identified trials⇓. We identified 49
randomised trials reporting the effect of bone marrow stem cells
on ejection fraction for cardiac disease (appendix 6). Length of
follow-up ranged from three months to 65 months, with modal
duration of six months. Each trial had between one and 13
reports. There were 133 reports in total (see appendix 4 for the
list of trials and reports). We identified one study during the
search in which the focus was on safety alone (appendix 7).
Discrepancies in design, methods, or results
We identified 604 instances of discrepancy (appendices 1-3)
within a trial report or between reports of that trial. We identified
44 discrepancies in the reports of the study on safety. There
were many types of discrepancy, as shown by the examples in
table 1⇓. Table 2 shows examples from the trials of phenomena
that are unusual but were not counted as discrepancies⇓.
Many aspects of the reports contained discrepancies. Even the
primary endpoint was not spared (t09/308, t14/301, t19/305).
Sometimes the discrepancies seemed to affect whether the
difference between trial arms was significant (t10/301). Effect
size, defined as the increment in ejection fraction from bone
marrow stem cell therapy, ranged from −3.9 to 14 percentage
units. Numbers of discrepancies in individual trials across all
their reports ranged from 0 to 89.
There was a significant correlation between the number of
discrepancies and the reported ejection fraction effect size
(Spearman’s r=0.4, P=0.005, fig 2⇓). There were only five
studies with no discrepancies, and these showed a mean effect
size of −0.4%, with this average weighted by sample size. The
24 trials with one to 10 discrepancies showed mean effect size
of 2.1%; the 12 with 11 to 20 discrepancies showedmean effect
size of 3.0%; the three with 21-30 discrepancies showed mean
effect size of 5.7%; and five high discrepancy trials, with over
30 discrepancies each, showed a mean effect size of 7.7% (fig
3⇓).
Publication bias
The funnel plot (appendix 8) did not show significant asymmetry
(Egger’s test P=0.4) that would suggest publication bias.
Discrepancies and risk of bias
The results of the exploratory univariate and multivariate
analyses are presented in appendix 9. Only the number of
discrepancies (P<0.001) and sequence generation (P=0.03)
remained significant contributors to the effect size (adjusted
R2=0.38, P<0.001).
Meta-analysis of studies providing
information on uncertainty of effect size
We could adequately extract the standard error of the effect size
estimate in only 31 trials to allow a formal meta-analysis to be
conducted using this information (appendix 10). The weighted
mean effect size was 0.0 (95% confidence interval −4.67 to
4.65) for trials with no discrepancies; 1.9 (0.30 to 3.57) for trials
with 1-10 discrepancies; 4.6 (1.64 to 7.61) for trials with 11-20
discrepancies; 4.4 (−0.97 to 9.75) for trials with 21-30
discrepancies; and 10.4 (8.44 to 12.36) for trials with more than
30 discrepancies.
Discussion
Whenever we present scientific information we risk introducing
conflicting statements that form discrepancies. Our study shows
that scientists who achieve progressively better consistency of
reporting find progressively smaller effects on ejection fraction
of treatment with bone marrow stem cells. In trials with a
discrepancy count of zero, the ejection fraction effect seems to
be zero.
Study limitations
We were unable to blind ourselves to effect size because this
was embedded within the report itself. There might be additional
unidentified discrepancies. Our work involved developing newly
derived mathematical limits on what is possible (appendix 11).
There could be other such limits that have not yet been
established. We invite readers to contribute either new
discrepancies or new general methods for identifying the
impossible.
Our method of counting discrepancies is imperfect because there
is no universally accepted convention. We have tried to be
consistent (appendices 1-3) but are open to suggestions from
readers. Some readers might consider what we list as a single
discrepancy to be several (for example, multiple repetitions of
the same contradiction) or what we consider several to be just
one (arguing, for example, that multiple discrepancies in a table
might have been values from a different trial pasted into a
manuscript accidentally).
We have taken a simple approach of including all trials,
including some that we have previously identified as containing
discrepancies and that showed a large effect of stem cells.5With
exclusion of these four trials, Spearman’s rank correlation
coefficient in figure 2 is lower at 0.3 (P=0.03) but similar. We
were able to examine only studies whose results have been
reported. We examined clinical trial registries but many trials
seem to have sped through to publication, with the registration
step skipped.
In some cases it was not clear whether a trial was randomised.
Previous meta-analysts have handled the confusion in
contradictory ways, with some trials being classified as
randomised in one meta-analysis and non-randomised in
others.1 15 16 Our policy considered a trial eligible if an author
of the primary report stated at any stage that the trial was
randomised. We recognise that other conventions for inclusion
would also have been possible. This will remain a challenge as
long as primary authors find the distinction puzzling.
Our main analysis is weighted simply by sample size because
this was available in every trial. In formal meta-analysis it is
ideal to weight by a function of the reciprocal of the square of
the standard error of the effect size estimate, but more than a
third of the trials did not provide this information. For those
trials that did provide sufficient data to weight the effect size
estimates in this way, we conducted a formal meta-analysis
(shown in appendix 10).
We have not attempted to control for the fact that some trials
issued more reports than others, and different reports gave
information to different levels of depth. It is difficult to
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2014;348:g2688 doi: 10.1136/bmj.g2688 (Published 29 April 2014) Page 3 of 9
RESEARCH
satisfactorily control for this because sometimes the multiple
reports are pure duplication, sometimes they cover
non-overlapping information, and sometimes they are
contradictory.
We excluded five reports because they were in Chinese language
journals to which we had no access.17-23We do not know to what
extent this access limitation might have biased our results.
Although it might have been possible to use additional routes
to obtain the full text, and then arrange a translation, the
translation process could always be suspected as a source of
imperfection.
Results in context of other similar work
There seem to be no other studies exploring the relation between
effect size of bone marrow stem cell therapy and the number of
discrepancies in the reports. Several meta-analyses have covered
bone marrow stem cell therapy for increasing ejection fraction
but have not discussed the discrepancies in the reports. They
all concluded that the average effect was a significant increase
in ejection fraction.1 3 This was reiterated in a Cochrane review4
and the recentMESS (meta-analysis of cardiac stem cell studies)
meta-analysis.24
Our findings expand on these meta-analyses. Our study concurs
that viewing all the studies together as a single entity, there is
on average a positive effect on ejection fraction. However, we
found that the positivity was not consistent across the spectrum
of discrepancy count. The studies with the most discrepancies
seem to be contributing most to the positivity, while the studies
with no discrepancies show a zero effect. Averaging effect size
across all studies might therefore not be wise because it does
not reflect their varying factual accuracy.
Standard meta-analyses include quality assessment, but this
does not seem to involve identifying or quantifying factual
discrepancies.5 Well conducted meta-analyses have somehow
classed many studies with numerous discrepancies as high
quality.1 3 25-27
Discrepancy count seems additive to a traditional assessment
of risk of bias (appendix 9). If our findings are verified by other
workers in other specialties, then addition of discrepancy
checking, and ideally cross checking with raw data, might make
meta-analysis more illuminating.
Possible explanations
We do not know the cause of the discrepancies. We have asked
for resolution of over 150 discrepancies through journals.5None
were resolved, although we found it triggered correspondence
from lawyers.
One possibility is that authors might feel pressure for results to
match expectations. One signal of a misguided desire to please
is the phenomenon of directed editing of rounded percentages
to force them to add up to 100%. In reality, correctly rounded
percentages should often not add up to 100% when there are
many categories.28 The effect of even a little bias can be
surprisingly dramatic.29 30
Secondly, exciting new treatments might be reported before full
checking. One sign of this, in the neighbouring specialty of
cardiomyocyte-derived stem cell therapy, is the insertion of the
word “randomised” into the title of the journal publication31 that
was not present in the manuscript finalised by the authors32 on
Pubmed Central. There were seven controls in total, but after
subtraction of the four who were not randomised and one who
was randomised to stem cells but refused treatment, the number
of randomised controls was only two. For the Lancet this was
a new low.
Thirdly, bone marrow stem cell therapy might be less effective
when it is carried out in a rigidly standardised way. Centres
with less attention to detail might incorporate an unnoticed
contaminant that enhances the effect of treatment. These centres
might produce reports with more discrepancies. In support of
this, just over a fifth of the trials (t07, t08, t09, t11, t21, t27, t33,
t35, t40, t43, t44, t49) showed ejection fraction effects of 7%
or more, but these trials accounted for more than half of all the
discrepancies.
The final possibility is that in the reports with the fewest
discrepancies, the ejection fraction effect might also have been
measured with least error. If so, the true effect of bone marrow
stem cells on ejection fraction is zero.
Implications for correctness of values
reported in trials
When trials provide full data, serious errors in reporting can
come to light, such as omitted patients,33 reclassification of
causes of death,34 35 or studies based on fictitious data.36 37 As
full data disclosure is rare, readers currently cannot estimate
how many trial reports are incorrect. It is essential that there is
open access to data.38
In our study, the reported standard deviation of the NYHA score
(New York Heart Association classification for chronic heart
failure) offers a unique window into correctness of reporting,
which does not require raw data. If NYHA data for individual
patients are fabricated, then the means and standard deviations
will remain mathematically possible.
It is only when standard deviations are not correctly calculated
from real NYHA values that mathematically impossible values
can arise. Of 11 trials reporting a standard deviation of NYHA,
the values in five (45%) are mathematically impossible.
The NYHA score is simple to measure, and the standard
deviation is simple to calculate. Ejection fraction effect is more
complex to measure and its statistical significance is more
complex to calculate. We are concerned that, if simple
calculations on simple variables are definitely incorrect in almost
half of trials, then themore subtle statistical statements regarding
more subtle variables might in most cases also be incorrect.
Implications for interpreting trial design
Readers need to know whether a trial is randomised or not, but
the reports were sometimes vague or even contradictory. Some
trials were initially reported as accepter-rejecter
(non-randomised) and later as randomised5 (t21, t41, t49). In
one, a later publication recalled the existence of a placebo
control group (t07r3). In this specialty, patients’ voluntary choice
is sometimes considered a form of randomisation, a policy
accepted by some journals (t21/102).5 39 Identical tables and
identical figures have inexplicably been presented as results of
different studies,5 with different names, different designs
(randomised versus accepter-rejecter), and different sample
sizes (t07r1, t07r10).
Journals could resolve such discrepancies but currently do not
consider this a priority5 40 (t07r1, t07r10, t21r5, t21r11, t49r1,
t49r3).
Implications for safety of bone marrow stem
cell therapy
The safety of bone marrow stem cell therapy is underlined by
a large report focusing on this.41-44 Unfortunately it too contains
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many discrepancies (appendix 7), including impossible
percentages and conflicts between tables and figures, perhaps
because the reassuring findings had to be made available with
urgency.
Implications for clinicians and researchers
If patients ask for advice on which bone marrow stem cell trial
to enter, we want to maximise the benefit to them, while
maximising their contribution to reliable evidence for future
patients. Unfortunately, these seem to be in conflict (fig 3⇓).
Sometimes researchers feel that only findings of positive effects
indicate scientific success. But meticulously reported studies
reporting neutral effects are vital contributions to science. It is
more valuable to have a reliable report of a small improvement
than an unreliable report of a large improvement. Error-free
reporting is difficult to achieve, as we have found in our own
experience.45 Only 10% of these trials were reported without
introducing discrepancies. We consider these to be the greatest
scientific successes, even though the effect size was
unfortunately zero.
Several lessons can be drawn for the design of future trials of
bone marrow stem cells. Prior registration on a public clinical
trial registry was not universal and would have been helpful in
distinguishing unambiguously between trials that were multiply
published or merely identical by coincidence.
We recommend that reports include a spreadsheet of all the data
used for construction of the tables, so that incorrect values could
be more easily identified. Readers should accept that authors
cannot avoid errors; in turn authors should correct errors
promptly and indicate clearly when later reports incorporate
corrections. It should be remembered that the 604 discrepancies
listed in appendices 1-3 are unlikely to be all the errors. They
are only those detectable by us without any information beyond
the published reports. Disclosing the individual patient data
could help to correct more errors.
It is important for studies using change in ejection fraction as
an endpoint to be properly designed to resist error and to have
adequate sample size to combat the effects of biological
variability. Left ventricular ejection fraction is a mutable
variable, which in some modalities is easily manipulated
innocently by clinicians who have prior beliefs on what a
realistic value should be for a particular patient. Sample size
planning can sometimes be erroneously omitted when clinicians
are enthusiastic to “demonstrate the effectiveness” of a treatment
seen as exciting.
Conclusions
It is difficult to avoid discrepancies in clinical trial reports. Trials
with progressively fewer discrepancies tend to find progressively
smaller effects on ejection fraction of bone marrow stem cell
therapy. The reason for this association is unknown. The few
trials for which the discrepancy count was zero had a stem cell
effect size that was also zero.
Notes added at proof stage: The institution of t07, t08, t21, and t49 is
recently reported to have identified evidence of misconduct46 and has
notified the city prosecutor. The institution of the SCIPIO trial31 is recently
reported to have requested that the publication be retracted.47
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Tables
Table 1| Spectrum of discrepancies in published reports of autologous bone marrow stem cell trials and enhancement of ejection fraction
ExamplesDiscrepancy
Authors published data as accepter-rejecter, and then later described similar (t41/101) or same (t07/101)
data as randomised (t08/101, t21/102, t49/103)
Studies that are reported by authors to be both
accepter-rejecter and randomised
100% of 6 patients referred to as 5 patients (t01/205) or 50% of 9 patients on a drug (t38/208). 20 patients
in 3 groups whose sizes add up to 19 (t16/201). Standard deviation (SD) impossibly wide (t43/308) or
mathematically impossible (t34/301) (explanation in appendix 11). Large identical changes in mean in
both recipients and control with no change in SD (t21/206)
Impossible numbers of patients, percentages, sums, or
summary statistics
Women present in early reports seem to have become men by later reports (t01/202, t21/203)Sex reclassification
NYHA class of 0 postoperatively, only in stem cell recipients, giving mean of 0.7 (t35/302). One patient
seems to have NYHA of −5 (t07/334)
Zero or negative NYHA class (which can only be I, II, III,
or IV)
Mean values of 2.38 (SEM 0.26) and 2.2 (SEM 0.20) reported as significantly different, but t test result
not significant (t22/301). Groups that differ with P<0.001 described as comparable (t07/305, t49/202).
Readers not informed of highly significant changes in control group, which if calculated show P values
as low as <1×10−108 (t07/352)
Indicating non-significant differences as significant, or
significant differences as non-significant (actively or by
omission)
Patients who died or were lost to follow-up were still taking drugs, reporting symptoms, and undergoing
tests (t41/201, t07/357, t07/358, t07/359, t07/360). Discrepancy over whether controls had sham injection
or how injection could reach stated position (t35/201, t35/202). Of 41 patients, at 3 years, 12 had died
or 10 had died, or perhaps none had died since all 41 reported their NYHA class at 3 years (t41/301,
t41/302, t41/303)
Conflicts in protocol or follow-up
Conflicts between figures and numerical data (t40/302, t29/305). Measurement spread increases but SD
shrinks (t46/301), or SD bars vary but SD stays same (t40/302, t40/303, t40/304, t40/305). More patients
on graph showing individuals’ EFs than were supposed to be in study (t42/302). Conflicts between tables
in numbers of patients (t28/301) or means and SDs (t27/307)
Fiddly figures: contradictions
EF effect of +7.1 (“P=0.05”), but assembling effects in two subgroups shows overall effect of +6.5 (P>0.05)
(t12/301)
Principal report is of significant effect, subsequent report
(presumably a correction) shows effect had been smaller
and non-significant
NYHA=New York Heart Association; SEM=standard error of mean; EF=ejection fraction.
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Table 2| Unusual phenomena not listed as discrepancies in published reports of autologous bonemarrow stem cell trials and enhancement
of ejection fraction
ExamplePhenomenon
75 patients randomised between control and stem cells but results shown only as averages that include
another 17 from uncontrolled cohort (t15r1). Significant stem cell effect was seen
Randomised results presented intermingled with
non-randomised
All patients had radionuclide SPECT LVEF, but results not shown and indicated to be “similar trends” to
echocardiographic EF, which showed significant stem cell effect (t42r1). In another trial all had radionuclide
LVEF but results not shown; instead MRI LVEF substudy results are shown (t25r2). Significant stem cell
effect was seen
Vanishing SPECT EF
Of patients with NYHA III and IV, within one year almost all the NYHA III patients died and almost all the
NYHA IV survived (t34r3)
Reversal of NYHA-mortality link
Given natural test-retest variability of EF in single individual, distribution of measurements across patients
should be substantially wider, but this is not always reflected in trial data (t33r1). Large stem cell effect was
seen
Extraordinarily narrowly distributed EFs during
follow-up
One study initially published as double blinded, but subsequently authors issued corrigendum whose only
effect was removal of words “double-blindedly” (t44r1). Large stem cell effect was seen
Delayed recollection of lack of blinding
Control subjects received infusion into coronary arteries of cell culture medium X-VIVO 10 (t17r4) “designed
to support the generation of Lymphokine Activated Killer cells”; manufacturer warns that it is “not approved
for human or veterinary use, or for application to humans or animals.”11 12 Significant stem cell effect was
seen
Controls received intracoronary injection of cell culture
medium not licensed for use in humans
Consent for randomisation obtained from relatives rather than patients (t33r1), or not described at all (t40r2,
t40r3, t44r1)
Unconventional informed consent process for
randomised controlled trial
Each patient can have many treatment episodes, each episode can be counted in more than one trial, each
trial can have more than one report (with different names), each report can appear in more than one
meta-analysis, and sum of patient counts from all meta-analysis can be totalled up, producing multiple levels
of multiple counting.6 13 14 (t49r1). Large stem cell effect was seen
St Ives syndrome
One study reported randomisation “using a nonparticipant in the study to pick a red ball . . . or blue ball,”
which seems insufficient guarantee of bias-resistance (t35r1). Large stem cell effect was seen
Balls
SPECT=single photon emission computed tomography ; LVEF=left ventricular ejection fraction; NYHA=New York Heart Association; SEM=standard error of mean;
EF=ejection fraction; MRI=magnetic resonance imaging.
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Figures
Fig 1 Identification of randomised controlled trials of autologous bone marrow stem cells for heart disease (EF=ejection
fraction)
Fig 2 Correlation between number of discrepancies in trial’s reports and ejection fraction (EF) effect size. Dot area is
proportional to trial’s sample size (Spearman’s r=0.4, P=0.005)
Fig 3 Mean ejection fraction (EF) effect size by number of discrepancies in trial’s reports. Error bars here show only SE of
mean effect size weighted for sample size across trials in each category. Formal meta-analytic confidence intervals, which
fully integrate sample size and uncertainty within each trial, are available only for subset of trials (see appendix 10)
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